Regulatory snapshot
Tracer Availability
Snapshot only — verify current status. Selected first approvals (approximate years). Availability, indications and reimbursement vary by country and change over time; confirm with the current label and your regulator/pharmacy. As referenced: 2026.
| Agent | Use | FDA | EMA |
|---|---|---|---|
| ⁶⁸Ga-DOTATATE | NET imaging (SSTR PET) | 2016 | 2016* |
| ¹⁷⁷Lu-DOTATATE (Lutathera) | GEP-NET therapy (PRRT) | 2018 | 2017 |
| ¹²³I-ioflupane (DaTscan) | Dopamine-transporter SPECT | 2011 | 2000 |
| ²²³Ra-dichloride (Xofigo) | Bone-metastatic mCRPC therapy | 2013 | 2013 |
| ⁶⁸Ga-PSMA-11 | Prostate PSMA PET | 2020 | — |
| ¹⁸F-DCFPyL (Pylarify) | Prostate PSMA PET | 2021 | — |
| ¹⁷⁷Lu-PSMA-617 (Pluvicto) | mCRPC therapy (post-taxane/ARPI) | 2022 | 2022 |
| ¹⁸F amyloid tracers | Brain amyloid PET | 2012–14 | 2013–14 |
* Related ⁶⁸Ga-DOTATATE/DOTATOC products approved separately. Years are indicative first-approval dates and are not a substitute for the current prescribing information.